Traditional Chinese medicine in the treatment of adverse reactions after TACE for primary hepatic carcinoma: Effect, mechanism, and potential advantages.

IF 6.7 1区 医学 Q1 CHEMISTRY, MEDICINAL Phytomedicine Pub Date : 2024-11-09 DOI:10.1016/j.phymed.2024.156244
Huai-Bang Li, Lin Huang, Jia-Yu Ni, Ruo-Yao Lin, Sheng-Yan Xi
{"title":"Traditional Chinese medicine in the treatment of adverse reactions after TACE for primary hepatic carcinoma: Effect, mechanism, and potential advantages.","authors":"Huai-Bang Li, Lin Huang, Jia-Yu Ni, Ruo-Yao Lin, Sheng-Yan Xi","doi":"10.1016/j.phymed.2024.156244","DOIUrl":null,"url":null,"abstract":"<p><p>Primary hepatic carcinoma is one of the most common malignant tumors. China is a major country for liver cancer, accounting for about 50 % of the patients worldwide. Although there are a variety of treatments for primary hepatic carcinoma, chemotherapy remains an important method, and transcatheter arterial chemoembolization (TACE) is a commonly used local chemotherapy. Currently, there are no effective therapeutic measures to target adverse reactions generated after chemoembolization. A new approach is needed to alleviate post-TACE syndrome. Clinical and experimental studies have shown that traditional Chinese medicine can reduce adverse reactions and improve clinical efficacy when combined with primary hepatic carcinoma treatment. This suggests that traditional Chinese medicine plays an important and irreplaceable role in alleviating adverse reactions after TACE. However, there is still a need for high-quality experimental and clinical studies to obtain evidence of effective treatment.</p>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"135 ","pages":"156244"},"PeriodicalIF":6.7000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.phymed.2024.156244","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Primary hepatic carcinoma is one of the most common malignant tumors. China is a major country for liver cancer, accounting for about 50 % of the patients worldwide. Although there are a variety of treatments for primary hepatic carcinoma, chemotherapy remains an important method, and transcatheter arterial chemoembolization (TACE) is a commonly used local chemotherapy. Currently, there are no effective therapeutic measures to target adverse reactions generated after chemoembolization. A new approach is needed to alleviate post-TACE syndrome. Clinical and experimental studies have shown that traditional Chinese medicine can reduce adverse reactions and improve clinical efficacy when combined with primary hepatic carcinoma treatment. This suggests that traditional Chinese medicine plays an important and irreplaceable role in alleviating adverse reactions after TACE. However, there is still a need for high-quality experimental and clinical studies to obtain evidence of effective treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药治疗原发性肝癌 TACE 后的不良反应:效果、机制和潜在优势。
原发性肝癌是最常见的恶性肿瘤之一。中国是肝癌大国,约占全球肝癌患者的 50%。尽管原发性肝癌的治疗方法多种多样,但化疗仍是一种重要方法,经导管动脉化疗栓塞术(TACE)是常用的局部化疗方法。目前,针对化疗栓塞后产生的不良反应还没有有效的治疗措施。因此需要一种新的方法来缓解 TACE 术后综合征。临床和实验研究表明,中药与原发性肝癌联合治疗可减轻不良反应,提高临床疗效。这表明,中药在缓解 TACE 后不良反应方面发挥着不可替代的重要作用。然而,仍需进行高质量的实验和临床研究,以获得有效治疗的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Phytomedicine
Phytomedicine 医学-药学
CiteScore
10.30
自引率
5.10%
发文量
670
审稿时长
91 days
期刊介绍: Phytomedicine is a therapy-oriented journal that publishes innovative studies on the efficacy, safety, quality, and mechanisms of action of specified plant extracts, phytopharmaceuticals, and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of herbal medicinal products, preparations, and purified compounds with defined and consistent quality, ensuring reproducible pharmacological activity. Founded in 1994, Phytomedicine aims to focus and stimulate research in this field and establish internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy, and safety of phytomedicines.
期刊最新文献
Dachengqi decoction ameliorated liver injury in liver fibrosis mice by maintaining gut vascular barrier integrity. 9-PAHSA ameliorates microvascular damage during cardiac ischaemia/reperfusion injury by promoting LKB1/AMPK/ULK1-mediated autophagy-dependent STING degradation. Green tea polyphenol alleviates silica particle-induced lung injury by suppressing IL-17/NF-κB p65 signaling-driven inflammation Jinwu Jiangu capsule attenuates rheumatoid arthritis via the SLC7A11/GSH/GPX4 pathway in M1 macrophages Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1